Home › Calculator › CRVS Dividend Calculator 2026
CRVS Dividend Calculator 2026
No dividendHealthcareCorvus Pharmaceuticals, Inc. · NASDAQ
Price: $10.45 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
CRVS is not a dividend-focused stock
CRVS pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
CRVS Dividend Yield
Corvus Pharmaceuticals, Inc. (CRVS) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CRVS pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Corvus Pharmaceuticals, Inc. (CRVS) — Dividend Analysis 2026
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
CRVS Dividend & DRIP — Frequently Asked Questions
Does CRVS pay a dividend?
No. Corvus Pharmaceuticals, Inc. (CRVS) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of CRVS?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does CRVS have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. CRVS has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to CRVS
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CRVS DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CRVS position with:
🌍 CRVS Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CRVS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CRVS Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CRVS Dividend Payment Schedule
CRVS pays quarterly — 4 times per year. Ex-div: —.
📊 CRVS vs Healthcare Benchmarks
How CRVS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CRVS sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CRVS Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-06-11 | 21,700 | $11.53 | $250.2K | ||
| A-Award | 2026-06-11 | 15,000 | $11.60 | $174.0K | ||
| A-Award | 2026-06-11 | 15,000 | $11.60 | $174.0K | ||
| A-Award | 2026-06-11 | 15,000 | $11.60 | $174.0K | ||
| A-Award | 2026-06-11 | 15,000 | $11.60 | $174.0K | ||
| A-Award | 2026-06-11 | 15,000 | $11.60 | $174.0K | ||
| Buy | 2026-05-18 | 1,932 | $12.01 | $23.2K | ||
| Buy | 2026-05-18 | 5,000 | $12.05 | $60.3K | ||
| A-Award | 2026-04-23 | 30,000 | $16.02 | $480.6K | ||
| M-Exempt | 2026-01-28 | 15,000 | $2.12 | $31.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare CRVS with peers: CRVS vs ABSI · CRVS vs AKBA · CRVS vs CMPX
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CRVS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Corvus Pharmaceuticals, Inc. (CRVS) is currently trading at $10.45, 61% below its 52-week high. It does not currently pay a regular dividend.
Does CRVS Pay a Dividend? Corvus Pharmaceuticals, Inc. Dividend Status
Corvus Pharmaceuticals, Inc. (CRVS) is a healthcare stock trading at $10.45. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest CRVS News
LiveProjected your CRVS DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.